Navigation Links
Ceres Trials Energy Crops at Georgia Biofuel Facility
Date:9/9/2008

THOUSAND OAKS, Calif., Sept. 9 /PRNewswire/ -- Energy crop company Ceres, Inc. announced today that it will trial improved switchgrass cultivars and high-biomass sorghum hybrids with Range Fuels, Inc. as part of a cooperative field trialing program at the site of Range Fuels' commercial-scale cellulosic ethanol plant, now under construction near Soperton, Georgia, about 150 miles southeast of Atlanta.

While wood residues will be the primary feedstock for this first-of-a-kind biorefinery, Ceres said that Range Fuels is also interested in better understanding the economic, environmental and logistical attributes of non-food, low-carbon grass species in the production of cellulosic biofuels. These grass species have a number of advantages: they have relatively rapid breeding cycles, they are highly efficient at storing sunlight in the form of carbohydrates, and they are widely adapted. Last spring, Ceres provided seed of new, high-yielding varieties that was planted in demonstration plots on Range Fuels' Soperton Plant site. The crops will be assessed for several years.

"The goal is to determine the best crop management, storage and handling practices for Georgia, and just as important, the performance of herbaceous biomass in Range Fuels' conversion process," said Anna Rath, Ceres vice president of commercial development. She noted that grass species, including both annuals and perennials, can provide a flexible and reliable supply of raw materials for fuel and power. "This is an important step in demonstrating that energy crops can be successfully and sustainably grown in the area surrounding the Range Fuels Soperton Plant site," she said.

Mitch Mandich, CEO of Range Fuels, said this project will inform future expansion decisions by the green energy company. "As we think about expanding production beyond our Soperton Plant, which will use woody biomass, we need to start understanding how a variety of high-yield, minimal impact biomass feed
'/>"/>

SOURCE Ceres, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
4. Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization
5. Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
6. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
7. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
8. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
9. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
10. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
11. Codexis Names David Anton VP Bioindustrials R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Clear Lake, MN (PRWEB) May 21, 2013 ... all-in-one trade show display solution for sales and marketing teams ... GLM Displays describes the kit as “everything you’ll need ... The Fusion Fabric Display Kit comes with a number of ... an all-around trade booth 20 feet by 20 feet in ...
(Date:5/20/2013)... , Collaboration with the ... in treatment of mastitis , ... to begin in the second half 2013 ... Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) will collaborate ... Service (ARS) to develop and trial products targeting the ...
(Date:5/20/2013)... Oven Industries Inc. announces a new laboratory ... controller has many outstanding user-friendly benefits. Contained all in ... wall as a self-contained temperature control system, which has ... device unique, as well as highly convenient for users. ... be used universally, which allows the user to use ...
(Date:5/20/2013)... , May 20, 2013 Today, at ... San Francisco , James McGough ... Psychiatry at the Semel Institute for Neuroscience and Human ... of Medicine at the University of California Los Angeles ... Child and Adolescent Psychopharmacology and ADHD at UCLA, presented ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... EDMONTON , May 11 ... biotechnology company focused on developing medical device,products for ... that it has,received regulatory concurrence from the United ... lead product, Occlusin(R) 500 Artificial,Embolization Device (OCL 500) ...
... Cumberland Pharmaceuticals Inc. ( CPIX) and Phebra Pty ... granted regulatory approval for marketing and sale in Australia . Acetadote, ... the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs ... , , ...
... N.J. , May 11 Scientists from Zymes LLC, ... the National Research Council of Canada presented ... California on April 28th .  The paper entitled, " ... induced rat model of Parkinson,s disease: The role of neurotrophic factors," ...
Cached Biology Technology:IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 3Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 2Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 3Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 4Acetadote(R) Approved in Australia for Treatment of Acetaminophen Poisoning 5Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California 2
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
(Date:5/20/2013)... effect of physical education (PE) on child weight, but ... the amount of time that elementary schoolchildren spent in ... study represents some of the first evidence of a ... forthcoming in the Journal of Health Economics . ... be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The research ...
(Date:5/20/2013)... COLUMBUS, Ohio New research suggests that a compound ... "superpower" to escape death. , By altering a ... re-educates cancer cells into normal cells that die as ... by inhibiting a process that would cause them to ... strict programming. This study in cells, led by Ohio ...
Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3Gym class reduces probability of obesity, study finds for first time 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 2The compound in the Mediterranean diet that makes cancer cells 'mortal' 3
... 26 SVOX, the leading provider of,embedded speech ... Processing Group of Siemens AG, according to SVOX ... IP of Siemens AG developed,over 25 years, including ... 60 patent families. The majority of the Professional,Speech ...
... Researchers have reported the first clinical evidence that ... an important milestone for this promising treatment which has ... issue of the journal Human Gene Therapy ... with severe rheumatoid arthritis conducted in Germany and led ...
... scientists celebrate 2009 as the bicentennial of Charles Darwin,s ... will gather at the University of Utah Feb. 25-27 ... violence, from war to domestic abuse and homicide. ... we use this knowledge to promote a more peaceful ...
Cached Biology News:SVOX Acquires Speech Processing Unit of Siemens AG, Expands Into Speech Recognition and Speech Dialog 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3The Evolution of Human Aggression: Feb. 25-27 conference 2The Evolution of Human Aggression: Feb. 25-27 conference 3The Evolution of Human Aggression: Feb. 25-27 conference 4
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
Eliminate electrical interference from any analog signal, without filtering. Ideal for electrophysiology applications like EKG, EMG, and EEGs. Removes 50/60hz noise and harmonics caused by grounding ...
... 400 Spun Columns, 10. *SizeSep 400 Spun ... 400 base pairs in length. - ... and pre-equilibrated in distilled water containing 0.15% Kathon ... ~ 400 base pairs. *Extremely useful ...
... GFX Purification Kit, 25 purifications. ... cDNA probesProvides efficient removal of unincorporated ... reactions with superior yields of labeled ... purification of cDNA labeled by either ...
Biology Products: